网站首页
概要
Insulin-like growth factor-binding protein 4 (IGFBP-4) inhibits the actions of IGF-I and IGF-II. The distribution of IGFBP-4 in tissues is dependent on its glycosylation state, however it preferentially targets connective tissue (Firth & Baxter; Qin et al.). IGFBP-4 is also produced in liver, adrenal glands, Leydig cells, developing embryos, spinal cord, and thymic cortex. IGFBP-4 inhibits WNT/β-catenin signaling, which downregulates prostate cancer proliferation (Zhu et al.). In vitro studies suggest that IGFBP-4 inhibits proliferation of neuroblastoma and glioma, while promoting bone loss in osteosarcoma and multiple myeloma (Durai et al.).
技术资料
| Document Type | 产品名称 | Catalog # | Lot # | 语言 |
|---|---|---|---|---|
| Product Information Sheet | Human Recombinant IGFBP-4 | 78164, 78164.1 | All | English |
| Safety Data Sheet | Human Recombinant IGFBP-4 | 78164, 78164.1 | All | English |
数据及文献
Data
(A) The biological activity of Human Recombinant IGFBP-4 was tested by its ability to inhibit IGF-II induced proliferation of FDC-P1 cells.Cell proliferation was measured using a fluorometric assay method. The EC50 is defined as the effective concentration of the growth factor at which cell proliferation is at 50% of maximum. The EC50 in the example above is less than 0.05 μg/mL. (B) 5 μg of Human Recombinant IGFBP-4 was resolved with SDS-PAGE under reducing (+) and non-reducing (-) conditions and visualized by Coomassie Blue staining. Human Recmbinant IGFBP-4 has a predicted molecular mass of 26.8 kDa.
